Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium‐90 resin microspheres in Taiwan: data from the RESIN registry
Rheun‐Chuan Lee(Taipei Veterans General Hospital), Chien‐Hung Chen(Chang Gung University), Ming‐Chih Ho(National Taiwan University Hospital), Yee Chao(National Cancer Center), Yung‐Fang Chen(China Medical University), Huei‐Lung Liang(Kaohsiung Veterans General Hospital), Po‐Chin Liang(National Taiwan University Hospital), Cheng‐Yuan Hsia(Taipei Veterans General Hospital), Pin‐Nan Cheng(National Cheng Kung University Hospital), Yi‐Sheng Liu(National Defense Medical Center), Chun‐Yen Yu(Chang Gung University), Hsueh‐Chou Lai(China Medical University), Yu‐Fan Cheng(Shanghai Medical College of Fudan University), Chien‐Fu Hung(Johns Hopkins University)
Cited by 3
Related Papers
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
|Journal of Clinical Oncology|2013|596
Hepatogastroenterology
|Hepatogastroenterology|2012|536